Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Acquired, inactivating mutations in Tet methylcytosine dioxygenase 2 (TET2) are detected in peripheral blood cells of a remarkable 5%–10% of adults greater than 65 years of age. They impart a hematopoietic stem cell advantage and resultant clonal hematopoiesis of indeterminate potential (CHIP) with skewed myelomonocytic differentiation. CHIP is associated with an overall increased risk of transformation to a hematological malignancy, especially myeloproliferative and myelodysplastic neoplasms (MPN, MDS) and acute myeloid leukemia (AML), of approximately 0.5% to 1% per year. However, it is becoming increasingly possible to identify individuals at greatest risk, based on CHIP mutational characteristics. CHIP, and particularly TET2-mutant CHIP, is also a novel, significant risk factor for cardiovascular diseases, related in part to hyper-inflammatory, progeny macrophages carrying TET2 mutations. Therefore, somatic TET2 mutations contribute to myeloid expansion and innate immune dysregulation with age and contribute to prevalent diseases in the developed world—cancer and cardiovascular disease. Herein, we describe the impact of detecting TET2 mutations in the clinical setting. We also present the rationale and promise for targeting TET2-mutant and other CHIP clones, and their inflammatory environment, as potential means of lessening risk of myeloid cancer development and dampening CHIP-comorbid inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 11×
“Abbreviations α-KGDDs Alpha-ketoglutarate- and Fe2+-dependent dioxygenases ARCH Age-related clonal hematopoiesis Arg1 Arginase 1 AML Acute myeloid leukemia CCUS Clonal cytopenia of undetermined significance CH Clonal hematopoiesis CHIP Clonal hematopoiesis of indeterminant potential CMML Chronic myelomonocytic leukemi…”
BackgroundInfluentialGenomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 1×
“Next-generation sequencing (NGS) has become increasingly important in the detection of genetic variants in myeloid malignancies [3,21,22].”
BackgroundClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531 · cited 8×
“Abbreviations α-KGDDs Alpha-ketoglutarate- and Fe2+-dependent dioxygenases ARCH Age-related clonal hematopoiesis Arg1 Arginase 1 AML Acute myeloid leukemia CCUS Clonal cytopenia of undetermined significance CH Clonal hematopoiesis CHIP Clonal hematopoiesis of indeterminant potential CMML Chronic myelomonocytic leukemi…”
BackgroundInfluentialClonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683 · cited 6×
“The involvement of hematological TET2-deficiency in the pathogenesis of atherosclerosis has been investigated at the cellular level [57,61].”
BackgroundInfluentialRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536 · cited 7×
“The involvement of hematological TET2-deficiency in the pathogenesis of atherosclerosis has been investigated at the cellular level [57,61].”
BackgroundInfluentialLandscape of genetic lesions in 944 patients with myelodysplastic syndromes
Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014) · Leukemia · doi:10.1038/leu.2013.336 · Cited by 1,532
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443 · cited 16×
“They found that vitamin C treatment mimics TET2 restoration in Tet2-deficient mouse HSPCs by increasing 5hmC formation, as seen in other studies [88].”
BackgroundInfluentialVitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells
Blaschke, K., Ebata, K. T., Karimi, M. M., Zepeda-Martínez, J. A., Goyal, P., Mahapatra, S., Tam, A., Laird, D. J., Hirst, M., Rao, A., et al. (2013) · Nature · doi:10.1038/nature12362 · Cited by 865 · cited 1×
“Vitamin C is an α-KGDD co-factor that has been shown to promote activity of TET enzymes [86].”
BackgroundPrediction of acute myeloid leukaemia risk in healthy individuals
Abelson, S., Collord, G., Ng, S. W. K., Weissbrod, O., Mendelson Cohen, N., Niemeyer, E., Barda, N., Zuzarte, P. C., Heisler, L., Sundaravadanam, Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0317-6 · Cited by 850 · cited 4×
“Importantly, models have been constructed that can predict the development of AML either months or years in advance of disease onset by analyzing the somatic molecular profiles or clinical parameters (notably red blood cell distribution width) of people with CHIP [48].”
BackgroundInfluentialTet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., et al. (2015) · Nature · doi:10.1038/nature15252 · Cited by 807 · cited 1×
“During the resolution of inflammation, TET2 normally recruits histone deacetylase 2 (HDAC2) to deacetylate IL6, thereby repressing its transcription and IL-6 levels [66].”
BackgroundClonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
Zink, F., Stacey, S. N., Norddahl, G. L., Frigge, M. L., Magnusson, O. T., Jonsdottir, I., Thorgeirsson, T. E., Sigurdsson, A., Gudjonsson, S. A., Gudmundsson, J., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769869 · Cited by 777
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia
Jan, M., Snyder, T. M., Corces-Zimmerman, M. R., Vyas, P., Weissman, I. L., Quake, S. R., & Majeti, R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004315 · Cited by 721
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression
Cimmino, L., Dolgalev, I., Wang, Y., Yoshimi, A., Martin, G. H., Wang, J., Ng, V., Xia, B., Witkowski, M. T., Mitchell-Flack, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.032 · Cited by 707 · cited 4×
“In a recent study, Cimmino et al. (2017) modeled restoration of TET2 expression using reversible transgenic RNAi mice to confirm its reversal of aberrant HSPC self-renewal.”
BackgroundInfluentialSano, S., Oshima, K., Wang, Y., MacLauchlan, S., Katanasaka, Y., Sano, M., Zuriaga, M. A., Yoshiyama, M., Goukassian, D., Cooper, M. A., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.037 · Cited by 699 · cited 2×
“A separate study arrived at similar conclusions, showing that Tet2-deficient mice treated with an NLRP3 inhibitor were protected against accelerated cardiac dysfunction [60].”
ResultSomatic mutations precede acute myeloid leukemia years before diagnosis
Desai, P., Mencia-Trinchant, N., Savenkov, O., Simon, M. S., Cheang, G., Lee, S., Samuel, M., Ritchie, E. K., Guzman, M. L., Ballman, K. V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0081-z · Cited by 619 · cited 1×
“However, mutations in other CHIP-related genes have been found to associate with increased risk of and accelerated time to AML development [48,85].”
BackgroundPopulation dynamics of normal human blood inferred from somatic mutations
Lee-Six, H., Øbro, N. F., Shepherd, M. S., Grossmann, S., Dawson, K., Belmonte, M., Osborne, R. J., Huntly, B. J. P., Martincorena, I., Anderson, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0497-0 · Cited by 604
Ascorbate regulates haematopoietic stem cell function and leukaemogenesis
Agathocleous, M., Meacham, C. E., Burgess, R. J., Piskounova, E., Zhao, Z., Crane, G. M., Cowin, B. L., Bruner, E., Murphy, M. M., Chen, W., et al. (2017) · Nature · doi:10.1038/nature23876 · Cited by 545 · cited 2×
“Similarly, Agathocleous et al. (2017) demonstrated that ascorbate (vitamin C) regulates TET2 function in hematopoietic stem cells (HSCs).”
BackgroundDorsheimer, L., Assmus, B., Rasper, T., Ortmann, C. A., Ecke, A., Abou-El-Ardat, K., Schmid, T., Brüne, B., Wagner, S., Serve, H., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2018.3965 · Cited by 470 · cited 1×
“The VAF of clonal populations was associated with the severity of the clinical outcome, suggesting a dose-response relationship [58].”
BackgroundMicrobial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host
Meisel, M., Hinterleitner, R., Pacis, A., Chen, L., Earley, Z. M., Mayassi, T., Pierre, J. F., Ernest, J. D., Galipeau, H. J., Thuille, N., et al. (2018) · Nature · doi:10.1038/s41586-018-0125-z · Cited by 406 · cited 1×
“Furthermore, another group found that microbial signals from the intestine appear to trigger the expansion of myeloid Tet2-deficient clones, where bacterial translocation in Tet2-knockout mice led to increased IL-6 production and myeloid expansion [71].”
BackgroundCai, Z., Kotzin, J. J., Ramdas, B., Chen, S., Nelanuthala, S., Palam, L. R., Pandey, R., Mali, R. S., Liu, Y., Kelley, M. R., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.10.013 · Cited by 394 · cited 1×
“Similarly, upregulated Il6 expression from HSPCs in murine Tet2-knockout mice (in response to acute inflammatory stress) led to apoptotic resistance via increased expression of pro-survival genes and decreased expression of pro-apoptotic genes [70].”
BackgroundBuscarlet, M., Provost, S., Zada, Y. F., Barhdadi, A., Bourgoin, V., Lépine, G., Mollica, L., Szuber, N., Dubé, M.-P., & Busque, L. (2017) · Blood · doi:10.1182/blood-2017-04-777029 · Cited by 383 · cited 1×
“Individuals with somatic variants in TET2 were found to have an elevated prevalence of self-reported asthma or chronic obstructive pulmonary disease (COPD), though the nature of this relationship is unclear [65].”
BackgroundZambetti, N. A., Ping, Z., Chen, S., Kenswil, K. J. G., Mylona, M. A., Sanders, M. A., Hoogenboezem, R. M., Bindels, E. M. J., Adisty, M. N., Van Strien, P. M. H., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.08.021 · Cited by 342
Ichiyama, K., Chen, T., Wang, X., Yan, X., Kim, B.-S., Tanaka, S., Ndiaye-Lobry, D., Deng, Y., Zou, Y., Zheng, P., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.005 · Cited by 327
Regulation of the epigenome by vitamin C
Young, J. I., Züchner, S., & Wang, G. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034228 · Cited by 319 · cited 1×
“They found that vitamin C treatment mimics TET2 restoration in Tet2-deficient mouse HSPCs by increasing 5hmC formation, as seen in other studies [88].”
ResultTet2 restrains inflammatory gene expression in macrophages
Cull, A. H., Snetsinger, B., Buckstein, R., Wells, R. A., & Rauh, M. J. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.08.001 · Cited by 295
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
Pang, W. W., Pluvinage, J. V., Price, E. A., Sridhar, K., Arber, D. A., Greenberg, P. L., Schrier, S. L., Park, C. Y., & Weissman, I. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222861110 · Cited by 277
Zhang, X., Su, J., Jeong, M., Ko, M., Huang, Y., Park, H. J., Guzman, A., Lei, Y., Huang, Y.-H., Rao, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3610 · Cited by 258 · cited 2×
“Other studies have shown that co-mutations in DNMT3A and TET2 increase the risk of maligna t transform tion compared to ith r mutation alone [47,48], which is concerning given that these gen s are frequently co-mu ated in MDS [3].”
BackgroundSekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., Litzow, M. R., Buckstein, R., Fang, M., Roulston, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2510 · Cited by 237 · cited 2×
“However, success of HMA treatment in MDS patients has been found to be inconsistent and dependent on particular combinations of mutations, though MDS patients are not currently denied HMA therapy based on the presence of certain mutations [45,46].”
BackgroundSelf-citationDeregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
Gañán-Gómez, I., Wei, Y., Starczynowski, D. T., Colla, S., Yang, H., Cabrero-Calvo, M., Bohannan, Z. S., Verma, A., Steidl, U., & Garcia-Manero, G. (2015) · Leukemia · doi:10.1038/leu.2015.69 · Cited by 236
An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis
Abegunde, S. O., Buckstein, R., Wells, R. A., & Rauh, M. J. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2017.11.002 · Cited by 230 · cited 2×
“Upon prolonged plating with TNF-α, HSPCs with inactivating TET2 mutations developed a resistance to apoptosis and a propensity for myeloid differentiation [69].”
BackgroundSelf-citationHematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis
Arends, C. M., Galan-Sousa, J., Hoyer, K., Chan, W., Jäger, M., Yoshida, K., Seemann, R., Noerenberg, D., Waldhueter, N., Fleischer-Notter, H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0047-7 · Cited by 194 · cited 1×
“CHIP is a term used to describe individuals with hematological malignancy-associated somatic mutation(s) in the absence of other hematological malignancy diagnostic criteria [13,31].”
BackgroundIntravenous Vitamin C and Cancer: A Systematic Review
Fritz, H., Flower, G., Weeks, L., Cooley, K., Callachan, M., McGowan, J., Skidmore, B., Kirchner, L., & Seely, D. (2014) · Integrative Cancer Therapies · doi:10.1177/1534735414534463 · Cited by 124
Zhao, H., Zhu, H., Huang, J., Zhu, Y., Hong, M., Zhu, H., Zhang, J., Li, S., Yang, L., Lian, Y., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2017.12.009 · Cited by 112
Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans
Kaasinen, E., Kuismin, O., Rajamäki, K., Ristolainen, H., Aavikko, M., Kondelin, J., Saarinen, S., Berta, D. G., Katainen, R., Hirvonen, E. A. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09198-7 · Cited by 92 · cited 1×
“Interestingly, a family heterozygous for a truncating TET2 mutation had multiple cases of lymphoma among affected individuals but no abnormal cardiovascular phenotype [63].”
BackgroundUncompromised 10-year survival of oldest old carrying somatic mutations in DNMT3A and TET2
van den Akker, E. B., Pitts, S. J., Deelen, J., Moed, M. H., Potluri, S., van Rooij, J., Suchiman, H. E. D., Lakenberg, N., de Dijcker, W. J., Uitterlinden, A. G., et al. (2016) · Blood · doi:10.1182/blood-2015-12-685925 · Cited by 49 · cited 1×
“In addition, variants in TET2 and DNMT3A do not significantly lower the 10-year survival rate for elderly individuals (>85-year old) [84].”
Background
Cited by
The longitudinal dynamics and natural history of clonal haematopoiesis
Fabre, M. A., de Almeida, J. G., Fiorillo, E., Mitchell, E., Damaskou, A., Rak, J., Orrù, V., Marongiu, M., Chapman, M. S., Vijayabaskar, M. S., et al. (2022) · Nature · doi:10.1038/s41586-022-04785-z · Cited by 374
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation
Yeaton, A., Cayanan, G., Loghavi, S., Dolgalev, I., Leddin, E. M., Loo, C. E., Torabifard, H., Nicolet, D., Wang, J., Corrigan, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1146 · Cited by 94
Das, A. B., Smith-Díaz, C. C., & Vissers, M. C. M. (2020) · Haematologica · doi:10.3324/haematol.2020.259283 · Cited by 25
Tet2 deficiency–induced expansion of monocyte-derived macrophages promotes liver fibrosis
Feng, J., Wu, B., Li, Y., Sun, P., Liu, Q., Xiao, Q., Cai, J.-B., Zheng, Y., Chen, H., Xu, Y., et al. (2026) · Journal of Experimental Medicine · doi:10.1084/jem.20251114 · Cited by 6
“Notably, TET2 mutations in myeloid cells are detected in ∼ 10% of individuals over 65 years old, making CHIP significantly more prevalent in the elderly (Ferrone et al., 2020; Jaiswal and Ebert, 2019; Genovese et al., 2014).”
Metadata
- Authors
- Ferrone, C. K., Blydt-Hansen, M., & Rauh, M. J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-01-17
- Volume
- 21
- Issue
- 2
- Pages
- 626
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2999438278
- Cited by
- 74
- References
- 43
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.